View Exam | PowerPak

1. Which of the following endocrine therapy resistance mechanisms are addressed by CDK4/6 inhibitors?

A. Loss of ER expression B. Gain of growth factor expression C. Alteration of signaling pathway D. Changes to cell cycle regulators

2. SA is receiving ribociclib plus letrozole for metastatic HR+, HER-2- breast cancer. Soon after initiating therapy, her liver functions become elevated. At 6 weeks, her AST level is 3.5 times the upper limit of normal (ULN), her ALT level is 2.5 times ULN, and her bilirubin level is twice the ULN. What ribociclib dose modification, if any, would you recommend?

A. Withhold until grade 1 or lower; resume at the same dose B. Make no modifications until grade 3 toxicity C. Discontinue ribociclib D. Withhold until grade 1 or lower; resume at the next lower dose

3. KW is a 78-year-old woman who has battled HR+, HER-2-metastatic breast cancer for 7 years. She has received multiple endocrine therapies (anastrozole, tamoxifen) and more recently, single-agent chemotherapies (paclitaxel, capecitabine). Which therapy are you MOST likely to recommend for her?

A. Exemestane, everolimus B. Gemcitabine C. Palbociclib, letrozole D. Abemaciclib

4. What is 1 potential explanation for higher single-agent activity from abemaciclib compared with palbociclib or ribociclib?

A. Abemaciclib has fewer “off-target” effects due to greater specificity for CDK4 and CDK6. B. Abemaciclib's greater affinity for CDK4, versus CDK6, leads to less neutropenia and higher tolerance of therapy. C. Abemaciclib is administered as a 3 week on, 1 week off regimen, while the others are administered daily. D. It is an irreversible inhibitor of CDK4/6, while the others are reversible inhibitors.

5. What is the crucial time window in which neutropenia is most likely to develop in patients receiving CDK4/6 inhibitors?

A. Two to 3 weeks after initiating therapy B. During the first 2 weeks of therapy C. Typically, during the first 2 weeks of cycle 2 D. Neutropenia may manifest at any time during therapy.

6. What is the primary role of the pharmacist on the healthcare team managing a patient with HR+, HER-2-breast cancer?

A. To monitor therapy adherence and drug-associated toxicity B. To perform financial clearance for drug therapy C. To coordinate the treatment team D. To supervise administration of therapies

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following endocrine therapy resistance mechanisms are addressed by CDK4/6 inhibitors?

3. KW is a 78-year-old woman who has battled HR+, HER-2-metastatic breast cancer for 7 years. She has received multiple endocrine therapies (anastrozole, tamoxifen) and more recently, single-agent chemotherapies (paclitaxel, capecitabine). Which therapy are you MOST likely to recommend for her?

4. What is 1 potential explanation for higher single-agent activity from abemaciclib compared with palbociclib or ribociclib?

5. What is the crucial time window in which neutropenia is most likely to develop in patients receiving CDK4/6 inhibitors?

6. What is the primary role of the pharmacist on the healthcare team managing a patient with HR+, HER-2-breast cancer?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following endocrine therapy resistance mechanisms are addressed by CDK4/6 inhibitors?

3. KW is a 78-year-old woman who has battled HR+, HER-2-metastatic breast cancer for 7 years. She has received multiple endocrine therapies (anastrozole, tamoxifen) and more recently, single-agent chemotherapies (paclitaxel, capecitabine). Which therapy are you MOST likely to recommend for her?

4. What is 1 potential explanation for higher single-agent activity from abemaciclib compared with palbociclib or ribociclib?

5. What is the crucial time window in which neutropenia is most likely to develop in patients receiving CDK4/6 inhibitors?

6. What is the primary role of the pharmacist on the healthcare team managing a patient with HR+, HER-2-breast cancer?

« Return to Activity

Customers who Purchased
this Activity also Purchased